EX-FILING FEES

Calculation of Filing Fee Tables
S-4
Fulcrum Therapeutics, Inc.

Table 1: Newly Registered and Carry Forward Securities	☐Not Applicable

		Security Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial Effective Date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to be Paid	1	Equity	Common Stock, par value $0.001 per share	Other	1,569,100,441		$ 5,225.10	0.0001381	$ 0.72
Fees Previously Paid
Carry Forward Securities
Carry Forward Securities
			Total Offering Amounts:				$ 5,225.10		$ 0.72
			Total Fees Previously Paid:						$ 0.00
			Total Fee Offsets:						$ 0.00
			Net Fee Due:						$ 0.72

Offering Note

	Amount of Securities to be Received or Cancelled	Value per Share of Securities to be Received or Cancelled	Total Value of Securities to be Received or Cancelled	Cash Consideration Received by the registrant	Cash Consideration (Paid) by the registrant	Maximum Aggregate Offering Price
¹	Rule 457(f) Fee Calculation Details 1. Represents the maximum number of shares of Common Stock, par value $0.001 per share ("Fulcrum Common Stock"), of Fulcrum Therapeutics, Inc. ("Fulcrum"), that are expected to be issued (or become issuable) to equityholders of Slate Medicines, Inc.("Slate") in the proposed merger of Fusion Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Fulcrum, with and into Slate, with Slate surviving the merger, and as part of the same overall transaction, Slate will merge with and into Fusion Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Fulcrum, with Fusion Merger Sub II, LLC continuing as a wholly owned subsidiary of Fulcrum and the surviving entity of the merger. The amount of Fulcrum common stock to be registered includes the estimated maximum number of shares of Fulcrum common stock that are expected to be issued (or become issuable) pursuant to the merger, without taking into account the effect of a reverse stock split of Fulcrum's common stock, assuming an estimated pre-split exchange ratio (which is subject to adjustment prior to the closing of the merger) of approximately 24.8186 shares of Fulcrum common stock for each outstanding share of common stock of Slate. 2. Estimated solely for the purpose of calculating the registration fee under Rule 457(f)(2) under the Securities Act of 1933, as amended. Slate is a private company, no market exists for its securities, and Slate has an accumulated capital deficit. Therefore, the proposed maximum aggregate offering price is calculated based on an aggregate offering amount equal to one-third of the aggregate par value of the Slate Common Stock that will be exchanged in the Merger. 3. In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any securities that may from time to time be offered or issued resulting from forward or reverse stock splits, stock dividends or similar transactions.
	1,569,100,441	$ 0.00000333	$ 5,225.10			$ 5,225.10

Table 2: Fee Offset Claims and Sources	☑Not Applicable

		Registrant or Filer Name	Form or Filing Type	File Number	Initial Filing Date	Filing Date	Fee Offset Claimed	Security Type Associated with Fee Offset Claimed	Security Title Associated with Fee Offset Claimed	Unsold Securities Associated with Fee Offset Claimed	Unsold Aggregate Offering Amount Associated with Fee Offset Claimed	Fee Paid with Fee Offset Source
Rules 457(b) and 0-11(a)(2)
Fee Offset Claims
Fee Offset Sources
Rule 457(p)
Fee Offset Claims
Fee Offset Sources

Table 3: Combined Prospectuses	☑Not Applicable

	Security Type	Security Class Title	Amount of Securities Previously Registered	Maximum Aggregate Offering Price of Securities Previously Registered	Form Type	File Number	Initial Effective Date